Congress of the European Society of Clinical Microbiology and Infectious Diseases

Vienna, Austria 11 April 2025 - 15 April 2025

Dual therapy as good as three-drug HIV regimen in patients coinfected with TB

In the treatment of HIV in individuals who are receiving rifampin-based therapy for tuberculosis, a two-drug antiretroviral (ART) regimen comprising double-dose dolutegravir plus lamivudine compares favourably with a three-drug regimen of efavirenz, tenofovir, and lamivudine in terms of suppressing viral load, as shown in a study.

Dual therapy as good as three-drug HIV regimen in patients coinfected with TB

15 hours ago

Tapered vancomycin dosing reduces CDI recurrence

a day ago by

Tapering the dose of vancomycin over 2 weeks following initial 14-day therapy appears to work better than the 14-day fixed dosing at reducing the recurrence of Clostridioides difficile infection (CDI), as shown in the TAPER-V trial.

Tapered vancomycin dosing reduces CDI recurrence

a day ago

Temocillin a good alternative to carbapenems for bacteraemia

16 May 2025 by

The use of temocillin demonstrates comparable efficacy and safety to carbapenems for the targeted treatment of bacteraemia due to third-generation cephalosporin-resistant Enterobacterales (3GCR-E), primarily from urinary sources, reports a study.

Temocillin a good alternative to carbapenems for bacteraemia

16 May 2025

5-day antibiotic use viable in CAP patients with clinical stability

16 May 2025 by

Antibiotic treatment may be done for 5 days, as opposed to at least 7 days, in hospitalized patients with community-acquired pneumonia (CAP) who had achieved clinical stability by day 3 to 5, suggests a study presented at ESCMID Global 2025.

5-day antibiotic use viable in CAP patients with clinical stability

16 May 2025

Single-dose RSVPreF3 OA vaccine effective over 3 RSV seasons in seniors

07 May 2025 by

A single dose of adjuvanted respiratory syncytial virus (RSV) prefusion F protein–based vaccine (RSVPreF3 OA) is efficacious against RSV-related lower respiratory tract disease (RSV-LRTD) over three RSV seasons in older adults aged ≥60 years, according to results of the phase III AReSVi-006 trial presented at ESCMID Global 2025.

Single-dose RSVPreF3 OA vaccine effective over 3 RSV seasons in seniors

07 May 2025

BNT162b2 JN.1-adapted vaccine effective against COVID-19 hospitalization

06 May 2025 by

BNT162b2 JN.1-adapted vaccine provides protection against COVID-19–related hospitalization in Europe, a case-control study using the id.DRIVE platform has shown.

BNT162b2 JN.1-adapted vaccine effective against COVID-19 hospitalization

06 May 2025